Thermo Fisher Scientific expands its capabilities in France

Bourgoin early development hub broadens offerings for oral solid dose formulations

Tillotts Pharma announces the launch of Octasa 1600 mg Tablets in Canada

The introduction of Octasa 1600 mg to the Canadian market is expected to increase the options for UC patients managed with mesalazine.

Inflation and declining FDA drug approvals will pose challenges for pharma contract manufacturers in 2023, says GlobalData

FDA’s NME approvals declined substantially in 2022, causing overall New Drug Application (NDA) approvals to drop

Bridgewest Group launches new sterile injectable CDMO NovaCina

Lonza and ABL Bio collaborate on development and manufacture of new bispecific antibody product

Lonza supports development and manufacturing of ABL Bio’s bispecific antibody candidate with a complete and integrated end-to-end solution

Top management changes at IOL Chemicals and Pharmaceuticals

Vikas Vij has been appointed as Chief Executive Officer (CEO) of the company

Hutchmed completes rolling submission of NDA to USFDA for fruquintinib

NDA supported by data from global Phase III FRESCO-2 study in the U.S., Europe, Japan and Australia along with data from Phase III FRESCO study conducted in China

Lonza completes drug product manufacturing line in Visp

This expansion follows the groundbreaking of a large-scale commercial drug product facility in Stein (CH), in another milestone for Lonza’s Drug Product Services (DPS) offering

Evonik starts construction of US$220 million lipid innovation center in Lafayette

Cooperative agreement with U.S. Government to advance U.S. biopharma industry and ensure pandemic preparedness

Thermo Fisher Scientific opens cell therapy facility at University of California

The San Francisco facility is part of Thermo Fisher’s global pharma services network of more than 15 locations supporting cell and gene therapies.